MedPath

A NEW SCORING SYSTEM FOR PREDICTION OF PDA

Conditions
Patent Ductus Arteriosus
Prematurity; Extreme
Registration Number
NCT04270240
Lead Sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Brief Summary

Patent ductus arteriosus (PDA) is an important morbidity of that the diagnosis and treatment is controversy in premature infants. A number of scoring systems have been developed, including the findings of echocardiography on the diagnosis and treatment of PDA. This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Detailed Description

This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • informed consent obtained from parents
  • extremely preterm infants
  • infants born before 28 gestational week
Read More
Exclusion Criteria
  • lack of informed consent
  • chromosomal abnormality
  • cardiovascular abnormality
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants with Patent Ductus Arteriosus7 days

number of participants who diagnosed for hemodynamically significant PDA and had an elevated score of the newly developed system by us.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seda Yilmaz Semerci

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath